Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on October 23, 2024. The report addresses a specific corporate governance event regarding the departure of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resignation of Theresa Matkovits, Ph.D., as Chief Development Officer, effective October 23, 2024. The company stated this departure was to pursue another opportunity and was not the result of a material disagreement or change in the company's direction.
Outlook, Management Commentary, and Risks
Management has announced that Dr. Matkovits' responsibilities will be filled internally by James J. Ferguson, M.D. (Chief Medical Officer) and Susan Johansson, MS, CCRA (Vice President of Clinical Development). The company continues to work toward the consummation of a partnership on MAT2203, its oral formulation of the broad-spectrum drug amphotericin B. No new risks or contingencies were disclosed in this filing.
Investor Verification Checklist
- Confirm the effective date of Dr. Matkovits' resignation (October 23, 2024).
- Verify the internal succession plan involving Dr. Ferguson and Ms. Johansson.
- Monitor future updates regarding the partnership status of MAT2203.
- Review subsequent filings for any financial impact related to this leadership transition.